@article{c5c7d69b36a646928732dabec1d27e1a,
title = "Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy",
abstract = "Background and purpose: This study was undertaken to explore associations between plasma neurofilament light chain (pNfL) concentration (pg/ml) and disease activity in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and examine the usefulness of pNfL concentrations in determining disease remission. Methods: We examined pNfL concentrations in treatment-na{\"i}ve CIDP patients (n = 10) before and after intravenous immunoglobulin (IVIg) induction treatment, in pNfL concentrations in patients on maintenance IVIg treatment who had stable (n = 15) versus unstable disease (n = 9), and in clinically stable IVIg-treated patients (n = 10) in whom we suspended IVIg to determine disease activity and ongoing need for maintenance IVIg. pNfL concentrations in an age-matched healthy control group were measured for comparison. Results: Among treatment-na{\"i}ve patients, pNfL concentration was higher in patients before IVIg treatment than healthy controls and subsequently reduced to be comparable to control group values after IVIg induction. Among CIDP patients on IVIg treatment, pNfL concentration was significantly higher in unstable patients than stable patients. A pNFL concentration > 16.6 pg/ml distinguished unstable treated CIDP from stable treated CIDP (sensitivity = 86.7%, specificity = 66.7%, area under receiver operating characteristic curve = 0.73). Among the treatment withdrawal group, there was a statistically significant correlation between pNfL concentration at time of IVIg withdrawal and the likelihood of relapse (r = 0.72, p < 0.05), suggesting an association of higher pNfL concentration with active disease. Conclusions: pNfL concentrations may be a sensitive, clinically useful biomarker in assessing subclinical disease activity.",
keywords = "CIDP, disease activity, IVIg, neurofilament light chain",
author = "Mahima Kapoor and Aisling Carr and Martha Foiani and Amanda Heslegrave and Henrik Zetterberg and Andrea Malaspina and Laura Compton and Elspeth Hutton and Alexander Rossor and Reilly, {Mary M.} and Lunn, {Michael P.}",
note = "Funding Information: The authors are grateful to Dr Axel Petzold for the contribution of control samples. M.K. gratefully received funding from a patient's bequest, PhD scholarship from the Bethlehem Griffiths Research Foundation, and an Australian Government Research Training Program Scholarship. M.P.L. and A.S.C. are also supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018‐02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG‐720931), the Alzheimer Drug Discovery Foundation, USA (#201809‐2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF‐21‐831376‐C, #ADSF‐21‐831381‐C, and #ADSF‐21‐831377‐C), the Olav Thon Foundation, the Erling‐Persson Family Foundation, Stiftelsen f{\"o}r Gamla Tj{\"a}narinnor, Hj{\"a}rnfonden, Sweden (#FO2019‐0228), the European Union's Horizon 2020 research and innovation programme under Marie Sk{\l}odowska‐Curie grant agreement 860197 (MIRIADE), the European Union Joint Programme for Neurodegenerative Disorders (JPND2021‐00694), and the UK Dementia Research Institute at University College London. A multiuser equipment grant from Wellcome Trust funded the Simoa instruments. A.M. is supported by the Motor Neurone Disease Association (AMBRoSIA 972‐797 and NECTAR 974‐797 awards). A.M.R. is grateful to the BMA for the Vera Down Award and to the National Institute for Health Research University College London Hospitals Biomedical Research Centre. M.M.R. is grateful to the Medical Research Council (MRC), MRC Centre (grant G0601943), and National Institutes of Neurological Diseases and Stroke and Office of Rare Diseases (U54NS065712) for their support. A.J.H. is funded by the Wolfson Foundation and the UK Dementia Research Institute. Publisher Copyright: {\textcopyright} 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.",
year = "2022",
month = nov,
doi = "10.1111/ene.15496",
language = "English",
volume = "29",
pages = "3347--3357",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",
number = "11",
}